Arcellx, Inc. Cash Flow Statement
ACLX / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Arcellx, Inc. used $210M in operating cash flow and negative free cash flow of $213M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.02 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$228.9M | -$107.3M | -$70.7M | -$188.7M | -$65.0M |
| Depreciation & Amortization | $6.7M | $5.2M | $2.0M | $1.3M | $1.0M |
| Operating Cash Flow | -$210.3M | -$83.5M | $207.6M | -$99.3M | -$54.2M |
| Capital Expenditures | $2.3M | $13.4M | $21.4M | $2.3M | $5.8M |
| Free Cash Flow | -$212.6M | -$96.9M | $186.1M | -$101.6M | -$60.0M |
| FCF Margin | -953.9% | -89.8% | 168.7% | - | - |